Abstract:Objective Major depression disorder (MDD) is a harmful disorder, and the pathological mechanism remains unclear. The primary pharmacotherapy regimen for MDD is selective serotonin reuptake inhibitors (SSRIs), but fewer than 40% of patients with MDD are in remission following initial treatment. Neuroimaging biomarkers of treatment efficacy can be used to guide personalized treatment in MDD. This study aims to determine if cortical thickness can be used as a predictor for SSRIs. Methods A total of 126 first-episode, drug-naive MDD patients (MDDs) and 71 healthy controls (HCs) were enrolled in our study. Demographic data were collected according to the self-made case report form (CRF) at the baseline of all subjects. Magnetic resonance imaging (MRI) scanning was performed for all the participants at baseline, and all imaging was processed using the DPABISurf software. All MDDs were treated with SSRIs, and symptoms were assessed at both the baseline and 2 weeks using the 17-item Hamilton Rating Scale (HAMD-17). According to HAMD-17 total score improvement from baseline to the end of 2 weeks, the MDDs were divided into the non-responder group (defined as ≤ 20% HAMD-17 reduction) and responder group (defined as ≥50% HAMD-17 reduction). The receiver operating characteristic (ROC) curve was used to analyze the diagnostic value of MDDs' and HCs' cortical thickness for MDD. Correlation analysis was performed for the responder group and the non-responder group separately to identify the relationship between cortical thickness and SSRI treatment efficacy. To analyze whether cortical thickness was sufficient to differentiate responders and non-responders at baseline, we used ROC curve analysis. Results Significant decreases were found in the cortical thickness of the right supplementary motor area (SMA) in MDDs at the baseline (corrected by the Monte Carlo permutation correction, cluster-wise significant threshold at p < 0.025 and vertex-wise threshold at p = 0.001), area under the curve (AUC) = 0.732 [95% confidence interval (CI) = 0.233–0.399]. In the responder group, the cortical thickness of the right SMA was significantly thinner than in the non-responder group at baseline. There was a negative correlation ( r = −0.373, p = 0.044) between the cortical thickness of SMA (0 weeks) and HAMD-17 reductive rate (2 weeks) in the responder group. The results of ROC curve analyses of the responder and non-responder groups were AUC = 0.885 (95% CI = 0.803–0.968), sensitivity = 73.5%, and specificity = 96.6%, and the cutoff value was 0.701. Conclusion Lower cortical thickness of the right SMA in MDD patients at the baseline may be a neuroimaging biomarker for MDD diagnosis, and a greater extent of thinner cortical thickness in the right SMA at baseline may predict improved SSRI treatment response. Our study shows the potential of cortical thickness as a possible biomarker that predicts a patient's clinical treatment response to SSRIs in MDD.

Relations between cortical thickness, serotonin 1A receptor binding, and structural connectivity: A multimodal imaging study

565 – Abnormality of White Matter Structure and Resting State Brain Function in First-Episode, Treatment-Naive Patients with Major Depressive Disorder

Altered patterns of association between cortical thickness and subcortical volume in patients with first episode major depressive disorder: A structural MRI study.

Large-scale network dynamics in neural response to emotionally negative stimuli linked to serotonin 1A binding in major depressive disorder

Cortical Thickness and White Matter Integrity Abnormalities in Obsessive-Compulsive Disorder: A Combined Multimodal Surface-Based Morphometry and Tract-Based Spatial Statistics Study

Molecular, Functional, and Structural Imaging of Major Depressive Disorder

Dissociation of Glutamate and Cortical Thickness is Restricted to Regions Subserving Trait but Not State Markers in Major Depressive Disorder

Cortical Thickness Predicts Response Following 2 Weeks of SSRI Regimen in First-Episode, Drug-Naive Major Depressive Disorder: An MRI Study

Regional Increases of Cortical Thickness in Untreated, First-Episode Major Depressive Disorder.

Connectome Analysis of Functional and Structural Hemispheric Brain Networks in Major Depressive Disorder

Cortical thickness reductions associate with brain network architecture in major depressive disorder

Structural Connectivity of Thalamic Subnuclei in Major Depressive Disorder: an Ultra-High Resolution Diffusion MRI Study at 7-Tesla

Structural connectivity of dopaminergic pathways in major depressive disorder: An ultra-high resolution 7-Tesla diffusion MRI study

Surface Vulnerability of Cerebral Cortex to Major Depressive Disorder

Resting-state Functional Connectivity of the Raphe Nuclei in Major Depressive Disorder: A Multi-site Study.

Regional decreases of cortical thickness in major depressive disorder and their correlation with illness duration: a case-control study

Increased Prefrontal and Parietal Cortical Thickness Does Not Correlate with Anhedonia in Patients with Untreated First-Episode Major Depressive Disorders

Common and Specific Abnormalities in Cortical Thickness in Patients with Major Depressive and Bipolar Disorders

Preliminary Study of White Matter Abnormalities and Associations With the Metabotropic Glutamate Receptor 5 to Distinguish Bipolar and Major Depressive Disorders

Severity of current depression and remission status are associated with structural connectome alterations in major depressive disorder

PET Imaging of the Serotonin 1A Receptor in Major Depressive Disorder: Hierarchical Multivariate Analysis of [ C]WAY100635 Overcomes Outcome Measure Discrepancies